Related Experiment Videos
Cytokine production in obsessive-compulsive disorder
Biological Psychiatry
|November 1, 1996
Summary
Obsessive compulsive disorder (OCD) patients show normal cytokine production, unaffected by clomipramine (CMI) treatment. This study found no changes in interleukin production in OCD individuals before or after CMI therapy.
Area of Science:
- Immunology
- Neuroscience
- Psychiatry
Background:
- Reduced cytokine production is observed in major affective disorders.
- Clomipramine (CMI) treatment restores interleukin-1 beta (IL-1 beta) and interleukin-3-like activity (IL-3-LA) in depression recovery.
Purpose of the Study:
- To assess in vitro interleukin production in obsessive compulsive disorder (OCD) patients.
- To evaluate the effect of clomipramine (CMI) treatment on cytokine levels in OCD.
Main Methods:
- Peripheral blood mononuclear cells (PBMC) from 11 OCD patients and 11 healthy controls were analyzed.
- In vitro production of IL-1 beta, IL-2, and IL-3-LA was measured before and after 8 weeks of CMI treatment in OCD patients.
Main Results:
- OCD patients exhibited no alterations in cytokine production compared to healthy subjects.
- Clomipramine (CMI) treatment significantly improved OCD symptoms.
- No significant changes in IL-1 beta, IL-2, or IL-3-LA production were observed after 8 weeks of CMI treatment.
Conclusions:
- Obsessive compulsive disorder (OCD) itself does not alter interleukin production.
- Clomipramine (CMI) treatment does not affect interleukin production in OCD patients.